The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model

Background: Children with cystic fibrosis (CF) are at higher risk of severe respiratory syncytial virus (RSV) infection, which can lead to a decline in lung function. A monoclonal antibody, palivizumab (PMB), effectively prevents RSV hospitalizations; however, the high cost of PMB, approximately C$1...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Hum Vaccin Immunother
Asıl Yazarlar: McGirr, Ashleigh A., Schwartz, Kevin L., Allen, Upton, Solomon, Melinda, Sander, Beate
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2016
Konular:
Research Papers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5360124/
https://ncbi.nlm.nih.gov/pubmed/27768505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1235670
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller